Manufacturing Europe
SEE OTHER BRANDS

Your best source on manufacturing news from Europe

Press Releases

Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on Manufacturing Europe.

Europe $750+ Mn Spinal Navigation Market Analysis and Forecasts 2023-2024 & 2025-2032 - Innovation Drives Surge, Overcoming Cost Barriers / AI and Augmented Reality Revolutionize Real-Time Guidance - ResearchAndMarkets.com

Europe $750+ Mn Spinal Navigation Market Analysis and Forecasts 2023-2024 & 2025-2032 - Innovation Drives Surge, Overcoming Cost Barriers / AI and Augmented Reality Revolutionize Real-Time Guidance - ResearchAndMarkets.com

The "Europe Spinal Navigation Market: Analysis and Forecast, 2023-2032" report has been added to ResearchAndMarkets.com's offering. The Europe spinal navigation market was valued at $192.1 million in 2023 and is expected to reach $754.7 million by...

Chip Manufacturing Market Trends, Segmentation and Strategic Insights 2025–2034 | Exactitude Consultancy

Chip Manufacturing Market Trends, Segmentation and Strategic Insights 2025–2034 | Exactitude Consultancy

Luton, Bedfordshire, United Kingdom, June 13, 2025 (GLOBE NEWSWIRE) -- Market Overview The global chip manufacturing market, valued at approximately USD 500 billion in 2024, is on a dynamic trajectory of growth. With technological innovations and...

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke

MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the company has received CE Mark approval under the European Medical Device...

Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma – – Rademikibart reduced annualized exacerbations in patients with eosinophilic-driven type 2 asthma – – Data supports...

Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress

Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive initial results from the target enrollment group in the ongoing...

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical  Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Patients Required a Median of...

Europe Woodworking Power Tools Market Grows at 5.2% CAGR, Projected to Hit USD 475.6 Million by 2035

Europe Woodworking Power Tools Market Grows at 5.2% CAGR, Projected to Hit USD 475.6 Million by 2035

France's woodworking industry blends tradition with innovation, prioritizing sustainability, skilled craftsmanship, and raw material conservation for growth. NEWARK, DE, UNITED STATES, June 12, 2025 /⁨EINPresswire.com⁩/ -- Europe woodworking power...

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of preclinical data for IPH6501, its proprietary ANKET® targeting CD20 currently under investigation in a Phase 1/2...

Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs

Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency’s Committee for Veterinary Medicinal...

Europe Industrial Gases Market is Set for Strong Growth, To Reach USD 24.2 Billion by 2033

Europe Industrial Gases Market is Set for Strong Growth, To Reach USD 24.2 Billion by 2033

The Europe industrial gases market size valued at USD 17.3 billion in 2024, expected to reach USD 24.2 billion, CAGR of 3.57% during 2025-2033. FRANKFURT, HESSEN, GERMANY, June 11, 2025 /⁨EINPresswire.com⁩/ -- Europe Industrial Gases Market...

GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ® Named Early Access Program (AAC) in France

GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ® Named Early Access Program (AAC) in France

Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal...

Europe Builds AI Infrastructure With NVIDIA to Fuel Region’s Next Industrial Transformation

Europe Builds AI Infrastructure With NVIDIA to Fuel Region’s Next Industrial Transformation

France, Italy and the United Kingdom Support Regional Technology and Cloud Providers Domyn, Mistral AI, Nebius and Nscale to Deploy More Than 3,000 Exaflops of NVIDIA Blackwell Systems for Sovereign AI NVIDIA to Build AI Factory in Germany to...

Prime-Time M6 Coverage Crowns Yard Force iVR Series as France’s Next Big Leap in Wire-Free Lawn Care

Prime-Time M6 Coverage Crowns Yard Force iVR Series as France’s Next Big Leap in Wire-Free Lawn Care

A recent segment on M6’s flagship programme “Capital” cast the spotlight on Yard Force’s new iVR robotic mower family, hailing the range as a “game-changer... PARIS, FRANCE , FRANCE, June 12, 2025 /⁨EINPresswire.com⁩/ -- A recent segment on M6’s...

Study indicates Germany hemorrhaging industrial jobs

Study indicates Germany hemorrhaging industrial jobs

(MENAFN) Germany's industrial sector has shed over 100,000 jobs in the past year due to ongoing economic challenges, according to a report by consulting firm EY, as cited by the German Press Agency (dpa). Based on Federal Statistical Office data,...

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®

Patent portfolio now includes protection for manufacture, methods and compositions Provides AIM with patent protection for manufacturing Ampligen until 2041 OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)...

Leading Global Manufacturer Confirms First Batch of Pilot Plant Material Tested is Fumed Silica

Leading Global Manufacturer Confirms First Batch of Pilot Plant Material Tested is Fumed Silica

MONTREAL, June 12, 2025 (GLOBE NEWSWIRE) -- HPQ Silicon Inc. (“HPQ” or the “Company”) (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08), a technology company driving innovation in advanced materials and critical process development, is pleased to inform...

XPENG Announces New G6 and G9 Ultra Smart SUVs for Europe

XPENG Announces New G6 and G9 Ultra Smart SUVs for Europe

Redefining Performance, Design, and Intelligent Technology for the Next Generation of Electric Vehicles. Powered by Industry-Leading Powertrain Technology: 5C Supercharging Battery and 800V High-voltage SiC Platform across all trims. Charging...

Inter Scientific Supports Jupiter Research in Achieving EU Certification for First Handheld Liquid Inhalation Device

Inter Scientific Supports Jupiter Research in Achieving EU Certification for First Handheld Liquid Inhalation Device

LIVERPOOL, United Kingdom, June 12, 2025 (GLOBE NEWSWIRE) -- Inter Scientific is pleased to announce its role, in collaboration with Jupiter Research LLC, as the regulatory partner for the first handheld Liquid Inhalation Device to receive...

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

Median duration of response in FELIX study now 42.6 months after an additional 11 months of follow up More than half of patients still in remission at 24 months 38% of ongoing responders did not receive any subsequent therapy by month 33 Results...

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement supports development of a novel, in vivo...

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service